<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHYLERGONOVINE MALEATE</span><br/>(meth-ill-er-goe-noe'veen)<br/><span class="topboxtradename">Methergine<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">adrenergic antagonist (sympatholytic)</span>; <span class="classification">ergot alkaloid</span>; <span class="classification">oxytocic</span><br/><b>Prototype: </b>Ergotamine<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.2 mg tablet; 0.2 mg/mL injections</p>
<h1><a name="action">Actions</a></h1>
<p>Ergot alkaloid that induces rapid, sustained tetanic uterine contraction that shortens third stage of labor and reduces blood
         loss.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Administered after delivery of the placenta. It minimizes the risk of postpartal hemorrhage.</p>
<h1><a name="uses">Uses</a></h1>
<p>Routine management after delivery of placenta and for postpartum atony, subinvolution, and hemorrhage. With full obstetric
         supervision, may be used during second stage of labor.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ergot preparations; to induce labor; use prior to delivery of placenta; threatened spontaneous abortion;
         prolonged use; uterine sepsis; hypertension; toxemia; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Postpartum Hemorrhage</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.20.4 mg q612h until danger of atony passes (27 d) <span class="rdroute">IM/IV</span> 0.2 mg q24h (max: 5 doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Use parenteral routes only in emergencies.</li>
</ul><span class="adminroutetype">Oral</span><br/><ul>
<li> 					Note: Dosing should not exceed 1 wk. 				</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted or diluted in 5 mL of NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 0.2 mg or fraction thereof over 60 sec.  
               </p>
<ul>
<li>Do not use ampuls containing discolored solution or visible particles.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) unless otherwise directed. Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting</span> (especially with IV doses). <span class="typehead">CV:</span> Severe hypertensive episodes, bradycardia. <span class="typehead">Body as a Whole:</span> Allergic phenomena including <span class="speceff-life">shock</span>, ergotism. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <span class="classification">parenteral sympathomimetics</span>, other <span class="classification">ergot alkaloids</span>, <span class="classification">triptans</span> add to pressor effects and carry risk of hypertension; <b>amprenavir,</b> <b>delavirdine,</b> <b>efavirenz,</b> <b>indinavir,</b> <b>nelfinavir,</b> <b>ritonavir,</b> and <b>saquinavir</b> may decrease metabolism of <b>ergot</b> derivatives. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 515 min PO; 25 min IM; immediate IV. <span class="typehead">Duration:</span> 3 or more h PO; 3 h IM; 45 min IV. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Slowly metabolized in liver. <span class="typehead">Elimination:</span> Excreted mainly in feces, small amount in urine. <span class="typehead">Half-Life:</span> 0.52 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs (particularly BP) and uterine response during and after parenteral administration of methylergonovine
            until partum period is stabilized (about 12 h).
         </li>
<li>Notify physician if BP suddenly increases or if there are frequent periods of uterine relaxation.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report severe cramping for increased bleeding.</li>
<li>Report any of the following: Cold or numb fingers or toes, nausea or vomiting, chest or muscle pain.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>